| Michael Cully Warren Ii, | |
|
655 S Willow St Ste 128, Manchester, NH 03103-5723 | |
| (800) 995-2673 | |
| Not Available |
| Full Name | Michael Cully Warren Ii |
|---|---|
| Gender | Male |
| Speciality | Licensed Practical Nurse |
| Location | 655 S Willow St Ste 128, Manchester, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073127155 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | LP60925151 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael Cully Warren Ii, 655 S Willow St Ste 128, Manchester, NH 03103-5723 Ph: (800) 995-2673 | Michael Cully Warren Ii, 655 S Willow St Ste 128, Manchester, NH 03103-5723 Ph: (800) 995-2673 |
News Archive
Research led by a Johns Hopkins University biologist demonstrates the workings of a biochemical pathway that helps control glucose in the bloodstream, a development that could potentially lead to treatments for diabetes.
Curemark, a drug research and development company that focuses on the treatment of neurological diseases, has retained Rubenstein Public Relations to help raise national, regional, and industry awareness of the organization's research, treatments and founder, Dr. Joan Fallon. Curemark is developing an autism treatment that will be one of the first to address the underlying physiology of autism.
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg. This product is the generic version of Mayne Pharma's Doryx, which is a tetracycline-class antimicrobial.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin.
› Verified 5 days ago
Bethany Pinard, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3000 Goffs Falls Rd Ste 101, Manchester, NH 03103 Phone: 800-995-2673 | |
Ms. Hanna Ndakaziva, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 133 Eastern Ave, 203, Manchester, NH 03104 Phone: 603-965-8306 | |
Desiree Hunter, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3000 Goffs Falls Rd Ste 101, Manchester, NH 03103 Phone: 800-995-2673 | |
Linda Miller, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3000 Goffs Falls Rd, Ste 101, Manchester, NH 03111 Phone: 800-995-2673 | |
Darell Curry, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3000 Goffs Falls Rd Ste 101, Manchester, NH 03103 Phone: 800-995-2673 | |
Tre'ch'elle Owens, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 3000 Goffs Falls Road, Suite 101, Manchester, NH 03103 Phone: 800-995-2673 |